三甲降纤方抗肝纤维化临床观察  

Clinical Observation on the Treatment of Liver Fibrosis with Sanjia Jiangxian Formula(SJF,三甲降纤方)

作　　者：李双全[1] 

机构地区：[1]山西中医学院第二附属医院

出　　处：《山西中医》2005年第6期13-15,共3页Shanxi Journal of Traditional Chinese Medicine

摘　　要：目的:观察中药三甲降纤方抗肝纤维化的临床效果.方法:将124例肝纤维化患者随机分为治疗组及对照组各62例.治疗组口服三甲降纤方,每日1剂.每周用药5天;对照组口服扶正化瘀胶囊,每次5粒,每日3次;两组均治疗24周.结果:(1)肝纤维化血清学指标变化:治疗组HA、PCⅢ、CⅣ、LN含量较治疗前均显著下降(均P＜0.001);治疗组显效率为82.3%,对照组为14.5%,具有显著性差异(P＜0.001).(2)肝功能变化:两组治疗后血清ALT、TBIL均有显著改善(P＜0.005～0.001);治疗后血清AIb治疗组为41.2±10.1 g/L,对照组为35.9±8.2 g/L(P＜0.005).结论:三甲降纤方治疗慢性肝病有较好的抗纤维化和提升血清白蛋白作用.Objective： To observe the clinical effect of SJF in treating liver fibrosis. Method： 124 patients of with liver fibrosis were randomly divided into the treatment group（62 cases） and the control group （62 cases）. SJF was given to the treatment group once a clay for five clays per week. And Fuzheng Huayu Capsule （FHC,扶正化瘀胶囊） was given to the control group five pills each time,three times a day. Both the two groups were treated for 24 weeks. Results： （1） The serology indexes such as HA,PC Ⅱ , CIV and LN were decreased notablely in the treatment group （P 〈 0. 001）; 82.3% of the patients in the treatment group and 14. 5 % of the patients in the control group were significantly effective. The difference between the two groups was notable （P 〈 0. 001） . （2）Serous ALT and TBIL were both improved in the treatment group significantly （P 〈 0. 005 - 0. 001） ;Serous AIb in the treatment group and the control group were 41.2 ± 10. 1 g/L and 35.9 ± 8. 2 g/L respectively （P 〈 0. 005） . Conclusion：SJF has good effect of anti-fibrosis and increasing the serous albumin in treating chronic liver disease.

关 键 词：肝纤维化 症积 三甲降纤方 软坚散结 中医药疗法 

分 类 号：R575.2[医药卫生—消化系统]